Dana dhuwit perusahaan ultragenyx.com (RARE)

Ultragenyx - logo grafis emiten RARE

Ultragenyx Pharmaceutical is implementing revolutionary treatments for rare pathologies, creating medicine for forgotten patients. This success is backed by powerful R&D potential in mRNA and genome editing. Business stability is ensured by the production of unique drugs in US centers. Changes in cash asset volume demonstrate the issuer's liquidity, where 0.27 serves as the current metric level.

Dhuwit awis perusahaan: Ultragenyx Pharmaceutical Inc. (RARE) kanggo 04.07.2022 - 21.11.2026

Rincian metrik lan analitis perusahaan Ultragenyx (RARE)

Analisis kabeh metrik perusahaan:Ultragenyx Corp RARE
Produk merek ultragenyx.com

For Ultragenyx Pharmaceutical (RARE), whose revenue depends on high-cost insurance fund payouts for orphan drugs, the volume of physical cash serves as a key indicator of operational resilience. This metric aggregates liquid assets to assess the issuer's ability to cover obligations and fund R&D, allowing investors to determine the risk of capital shortages or the redundancy of idle reserves through the price action on the chart.

Analisis perusahaan pesaing

Volume dana dhuwit perusahaan TEM|QGEN - Cadangan dhuwit perusahaan|ionispharma.com - Dhuwit awis perusahaan|Sisa dhuwit perusahaan RGEN|Avidity Corp - Volume dana dhuwit perusahaan|CRISPR Therapeutics Corp - Gunggung dana dhuwit perusahaan|GeneDx Holdings (WGS) - Dana dhuwit perusahaan|BEAM - Aset likuid perusahaan|SRPT (Sarepta Therapeutics) - Volume dana dhuwit perusahaan|Dhuwit awis perusahaan Twist Bioscience Inc (TWST)|Volume dana dhuwit perusahaan TXG|Aset likuid perusahaan Intellia|Stoke - Dhuwit awis perusahaan|BLFS: Dhuwit awis lan setara dhuwit awis perusahaan|Wave Life Sciences Corp - Volume dana dhuwit perusahaan|Maze Therapeutics, Inc. (MAZE) - Dhuwit awis perusahaan|Sionna Therapeutics Inc (SION) - Dana dhuwit perusahaan|Dhuwit awis perusahaan Prime Medicine Corp|Dana dhuwit perusahaan tayshagtx.com|QURE - Posisi dhuwit perusahaan|Dhuwit awis perusahaan MGTX (MeiraGTx Holdings plc)|REGENXBIO (RGNX) - Posisi dhuwit perusahaan|Volume dana dhuwit perusahaan SLDB (Solid Biosciences Inc.)|Sisa dhuwit perusahaan OCGN|PacBio Corp - Volume dana dhuwit perusahaan|Benitec Biopharma Inc. (BNTC) - Dhuwit awis perusahaan|DSGN: Volume dana dhuwit perusahaan|Dhuwit awis lan setara dhuwit awis perusahaan RCKT|Dhuwit awis perusahaan FDMT|Dhuwit awis lan setara dhuwit awis perusahaan LXEO (Lexeo Therapeutics)|Volume dana dhuwit perusahaan KRRO|Editas Medicine, Inc. - Dhuwit awis lan setara dhuwit awis perusahaan|Dana dhuwit perusahaan Silence Therapeutics Inc. SLN|Volume dana dhuwit perusahaan ProQR Therapeutics N.V. PRQR|CDXS: Dhuwit awis perusahaan|Posisi dhuwit perusahaan Sangamo (SGMO)|NAUT (Nautilus Bio) - Dhuwit awis perusahaan|MGX - Aset likuid perusahaan|DTIL (Precision BioSciences Inc.) - Volume dana dhuwit perusahaan|generationbio.com (GBIO) - Aset likuid perusahaan|Dana dhuwit perusahaan Boundless Bio Inc (BOLD)|Volume dana dhuwit perusahaan Exicure Inc. (XCUR)|Dana dhuwit perusahaan imunon.com IMNN|Volume dana dhuwit perusahaan Phio Pharmaceuticals PHIO|Mustang Bio Inc - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan transcodetherapeutics.com|BNGO: Volume dana dhuwit perusahaan|Dhuwit awis lan setara dhuwit awis perusahaan APDN|BLUE (bluebirdbio.com) - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan ImmunoPrecise Antibodies IPA|Dhuwit awis perusahaan OMGA (omegatherapeutics.com)|Volume dana dhuwit perusahaan Singular Genomics Systems, Inc. (OMIC)|Volume dana dhuwit perusahaan RGLS (Regulus Therapeutics, Inc.)|Volume dana dhuwit perusahaan Syros SYRS|Telesis Bio, Inc. - Volume dana dhuwit perusahaan|TRACON Pharmaceuticals (TCON) - Dhuwit awis perusahaan|UBX: Volume dana dhuwit perusahaan